Products - Chronic kidney disease | Topic

Showing 12 products

Date | Title

New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Targeted-release budesonide for treating primary IgA nephropathy (TA1128)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 February 2026
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal) (TA1102)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 October 2025
Obinutuzumab with mycophenolate mofetil for treating lupus nephritis [ID6420]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
12 February 2026
Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 June 2026
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sibeprenlimab for treating IgA nephropathy [ID6604]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ferric citrate for managing iron and serum phosphorus levels in anaemia associated with chronic kidney disease [TSID12221]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Iptacopan for treating primary IgA nephropathy [ID6640]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [TSID12315]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ravulizumab for treating primary IgA nephropathy [TSID12313]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Chronic kidney disease Products

Filter

Product type

Guidance programme

Status

New and updated
1 selected

Showing 12 products

Targeted-release budesonide for treating primary IgA nephropathy (TA1128)

Iptacopan for treating complement 3 glomerulopathy (terminated appraisal) (TA1102)

Obinutuzumab with mycophenolate mofetil for treating lupus nephritis [ID6420]

Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]

Sibeprenlimab for treating IgA nephropathy [ID6604]

Ferric citrate for managing iron and serum phosphorus levels in anaemia associated with chronic kidney disease [TSID12221]

Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]

Iptacopan for treating primary IgA nephropathy [ID6640]

Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]

Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [TSID12315]

Ravulizumab for treating primary IgA nephropathy [TSID12313]

Chronic kidney disease Products

Filter

Product type

Guidance programme

Status

New and updated1 selected

Showing 12 products

New and updated
1 selected